Codexis Inc. reported total revenue of $8.6 million for the third quarter of 2025, compared to $12.8 million in the same period in 2024. Product gross margin improved to 64%, up from 61% the previous year. Research and development expenses were $13.9 million, while selling, general and administrative expenses totaled $11.2 million. The company reported a net loss of $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in the third quarter of 2024. Business highlights include a $37.8 million supply assurance agreement with Merck, expected to provide cash by the end of 2025, and a planned lease of a 34,000 square foot GMP facility. Codexis also noted continued commercial progress with 11 customers and 40 prospects in its pipeline. The company is reiterating its 2025 guidance and expects to issue 2026 guidance in early 2026.